Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma [Urologic Oncology]

Conclusion
This study demonstrated that dual PI3K/mTOR inhibition by apitolisib was less effective than was everolimus in mRCC, likely because full blockade of PI3K/mTOR signaling resulted in multiple on-target adverse events. VHL mutation and hypoxia-inducible factor 1α expression may be predictive of an mTOR inhibitor benefit, although prospective validation is required.

Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Powles, Lackner, Oudard, Escudier, Ralph, Brown, Hawkins, Castellano, Rini, Staehler, Ravaud, Lin, OKeeffe, Wang, Lu, Spoerke, Huw, Byrtek, Zhu, Ware, Motzer Tags: Clinical Trials, Translational Oncology Urologic Oncology Source Type: research